# QURE catalysts: uniQure N.V. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/qure/catalysts

> uniQure N.V. (QURE) has 1 upcoming catalyst. The next is the ifezuntirgene inilparvovec PDUFA date, May 1, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for QURE?

uniQure N.V. (QURE) has 1 upcoming catalyst. The next is the ifezuntirgene inilparvovec PDUFA date, May 1, 2027. Press release filed with the SEC (EX-99): "~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington's disease; PDUFA target action date of May 1, 2027 ~" [Calendar and source filings](https://sec-api.dev/companies/qure/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-122362, https://www.sec.gov/Archives/edgar/data/1590560/000110465926122362/tm2628930d1_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/companies/qure/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | uniQure N.V. |
| Ticker | QURE (Nasdaq) |
| SEC CIK | 1590560 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/qure |

## Cash runway

Cash $98.4M as of 2026-09-30; quarterly burn $47.8M; about 6.2 months of runway at that rate (XBRL company facts, accession 0001104659-26-122367).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2023 | [AMT-19 trial start](https://sec-api.dev/pdufa/amt-19) | QURE |  | completed | "In November 2023, the FDA cleared the IND application, and we started incurring additional costs for the Phase I/II clinical trial preparation." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1590560/000155837025007068/qure-20250331x10q.htm)) |
| Nov 2023 | [AMT-191 trial start](https://sec-api.dev/pdufa/amt-191) | QURE |  | completed | "In November 2023, the FDA cleared the IND application, and we began incurring additional costs for Phase I/II clinical trial preparation." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)) |
| Aug 2024 | [AMT-191 trial start](https://sec-api.dev/pdufa/amt-191) | QURE | Fabry disease | completed | "In August 2024, we announced that the first patient has been dosed." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1590560/000155837025009694/qure-20250630x10q.htm)) |
| Oct 2024 | [Sclerosis trial start](https://sec-api.dev/pdufa/sclerosis) | QURE |  | completed | "In October 2024, we announced the first patient was dosed in a Phase I/IIa clinical trial of AMT-162 for the treatment of SOD1-ALS." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1590560/000155837025001699/qure-20241231x10k.htm)) |
| November 21, 2024 | [Epilepsy trial start](https://sec-api.dev/pdufa/epilepsy) | QURE | refractory mTLE | completed | "Lexington, MA and Amsterdam, the Netherlands, November 21, 2024 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000155837024015883/qure-20241121xex99d1.htm)) |
| February 27, 2025 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Exhibit 99.1 uniQure Announces 2024 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000155837025001693/qure-20250227xex99d1.htm)) |
| Q2 2025 | [Ifezuntirgene inilparvovec NDA/BLA submission](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | scheduled | "After the completion of these interactions, the Company expects to provide a regulatory update in the second quarter of 2025, including the expected timing of a potential BLA submission." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000155837025001693/qure-20250227xex99d1.htm)) |
| May 9, 2025 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Exhibit 99.1 uniQure Announces First Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000155837025007065/qure-20250509xex99d1.htm)) |
| 2H 2025 | [AMT-191 interim data readout](https://sec-api.dev/pdufa/amt-191) | QURE |  | scheduled | "The Company plans to present initial data from the study in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000155837025007065/qure-20250509xex99d1.htm)) |
| July 29, 2025 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Exhibit 99.1 uniQure Announces Second Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000155837025009692/qure-20250729xex99d1.htm)) |
| September 24, 2025 | [Ifezuntirgene inilparvovec topline data readout](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | completed, positive | "On September 24, 2025, the Company announced positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington's disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590560/000110465925092740/qure-20250924x8k.htm)) |
| November 3, 2025 | [Ifezuntirgene inilparvovec NDA/BLA submission](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | completed | "In the final meeting minutes, and consistent with uniQure's November 3, 2025 press release, the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission. uniQure is carefully evaluating the feedback and plans to urgently request a follow-up meeting with the FDA to take place in the first quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465925118292/qure-20251204xex99d1.htm)) |
| November 10, 2025 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Exhibit 99.1 uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465925108802/qure-20251110xex99d1.htm)) |
| Dec 2025 | [Ifezuntirgene inilparvovec NDA/BLA submission](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | completed | "In December 2025, we announced that in the final meeting minutes, the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 were currently unlikely to provide the primary evidence to support a BLA submission." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1590560/000110465926087815/qure-20260630x10q.htm)) |
| Q1 2026 | [Ifezuntirgene inilparvovec NDA/BLA submission](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | scheduled | "The Company plans to discuss the AMT-130 data with the FDA at a pre-BLA meeting expected later this year, with the intention of submitting a BLA in the first quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590560/000110465925092740/qure-20250924x8k.htm)) |
| 1H 2026 | [Epilepsy interim data readout](https://sec-api.dev/pdufa/epilepsy) | QURE |  | scheduled | "The Company expects to present initial data from the study in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000155837025001693/qure-20250227xex99d1.htm)) |
| 1H 2026 | [Sclerosis interim data readout](https://sec-api.dev/pdufa/sclerosis) | QURE | SOD1 amyotrophic lateral sclerosis | scheduled | "AMT-162 for the treatment of SOD1 amyotrophic lateral sclerosis (ALS) - The Company continues to enroll patients in the Phase I/II EPISOD1 study and expects to present initial data in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000155837025009692/qure-20250729xex99d1.htm)) |
| 1H 2026 | [AMT-191 interim data readout](https://sec-api.dev/pdufa/amt-191) | QURE | Fabry disease | scheduled | "~ Presented initial data from Phase I/IIa study of AMT-191 in Fabry disease showing sustained increases in α - gal enzyme activity in patients with Fabry disease; additional clinical data expected in the first half of 2026 ~" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465925108802/qure-20251110xex99d1.htm)) |
| March 2, 2026 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Exhibit 99.1 uniQure Announces 2025 Financial Results and Provides Recent Company" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021890/qure-20260302xex99d1.htm)) |
| May 5, 2026 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Exhibit 99.1 uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/qure-20260505xex99d1.htm)) |
| Q3 2026 | [Ifezuntirgene inilparvovec NDA/BLA submission](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | scheduled | "On June 17, 2026, we announced our plan to submit a BLA for AMT-130 in Huntington's disease during the third quarter of 2026." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926077336/tm2618428-2_424b5.htm)) |
| July 29, 2026 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Exhibit 99.1 uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926087808/qure-20260729xex99d1.htm)) |
| Aug 2026 | [Ifezuntirgene inilparvovec NDA/BLA acceptance](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | completed | "We submitted our BLA for ifezuntirgene inilparvovec to the FDA in August 2026 and the FDA accepted the application for review in October 2026, with a PDUFA target action date of May 1, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)) |
| Sep 2026 | [Ifezuntirgene inilparvovec topline data readout](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | scheduled | "~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926087808/qure-20260729xex99d1.htm)) |
| November 2, 2026 | [Ifezuntirgene inilparvovec NDA/BLA acceptance](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | completed | "November 2, 2026, uniQure N.V. (the "Company") issued a press release announcing the U.S. Food and Drug Administration ("FDA") has accepted for review the Biologics License Application ("BLA") for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington's disease submitted under the Accelerated Approval pathway." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/tm2628699d1_8k.htm)) |
| November 4, 2026 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Announces Third Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122362/tm2628930d1_ex99-1.htm)) |
| May 1, 2027 | [Ifezuntirgene inilparvovec PDUFA date](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec) | QURE |  | scheduled | "~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington's disease; PDUFA target action date of May 1, 2027 ~" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122362/tm2628930d1_ex99-1.htm)) |

## Drugs

- [AMT-19](https://sec-api.dev/pdufa/amt-19): 
- [AMT-191](https://sec-api.dev/pdufa/amt-191): fabry disease
- [Epilepsy](https://sec-api.dev/pdufa/epilepsy): refractory mtle, refractory mesial temporal lobe epilepsy, severe medical needs, today
- [Ifezuntirgene inilparvovec](https://sec-api.dev/pdufa/ifezuntirgene-inilparvovec): huntington's disease, severe medical needs, today
- [Sclerosis](https://sec-api.dev/pdufa/sclerosis): sod1 amyotrophic lateral sclerosis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/qure/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "QURE catalysts: uniQure N.V. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/qure/catalysts

```bibtex
@misc{secapidev_companies_qure_catalysts_20261116,
  title        = {QURE catalysts: uniQure N.V. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/qure/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_qure_catalysts_20261116","title":"QURE catalysts: uniQure N.V. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/qure/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
